EVL (Endoscopic Variceal Ligation) Plus Vasoconstrictor vs.Ligation Plus PPI( Proton Pump Inhibitor) in the Control of Acute Esophageal Variceal Bleeding
Launched by NATIONAL SCIENCE AND TECHNOLOGY COUNCIL, TAIWAN · Apr 27, 2010
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
Previous studies showed that combination of endoscopic therapy with vasoconstrictor is better than either vasoconstrictor or endoscopic therapy alone in achieving the successful hemostatsis of acute variceal bleeding. The rationale of using vasoconstrictor is to enhance the efficacy of hemostasis by endoscopic therapy. Nowadays, endoscopic variceal ligation (EVL) has replaced endoscopic injection sclerotherapy (EIS) as the endoscopic treatment of choice in the arresting of acute esophageal variceal hemorrhage. EVL alone can achieve hemotasis up to 97% even in cases of active variceal hemorr...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The etiology of portal hypertension is cirrhosis.
- • Age ranges between 18-80 y/o.
- • Patients presenting with acute esophageal variceal bleeding proven by emergency endoscopy within 12 hours. (Acute esophageal variceal bleeding was defined as: (1) when blood was directly seen by endoscopy to issue from an esophageal varix (active bleeding), or (2) when patients presented with red color signs on their esophageal varices with blood in esophagus or stomach and no other potential site of bleeding identified (inactive bleeding).
- • EVL is performed after confirmation of acute esophageal variceal bleeding. Enrollment time: Immediately after EVL is completed and variceal bleeding is arrested.
- Exclusion Criteria:
- • Association with severe systemic illness, such as sepsis, COPD, uremia
- • Association with gastric variceal bleeding
- • Failure in the control of bleeding by emergency EVL
- • Moribund patients, died within 12 hours of enrollment
- • Uncooperative
- • Ever received EIS, EVL within one month prior to index bleeding
- • Child-Pugh's scores \> 13
About National Science And Technology Council, Taiwan
The National Science and Technology Council (NSTC) of Taiwan is a pivotal governmental body dedicated to advancing scientific research and technological innovation within the country. As a sponsor of clinical trials, the NSTC plays a critical role in facilitating and funding research initiatives that aim to enhance public health and medical advancements. By fostering collaboration between academia, industry, and healthcare institutions, the NSTC aims to translate scientific discoveries into practical applications that benefit society. Through its commitment to rigorous scientific standards and ethical practices, the NSTC ensures that clinical trials conducted under its auspices contribute to the global body of medical knowledge while prioritizing patient safety and efficacy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Gin-Ho Lo
Principal Investigator
E-DA Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials